Browse drugs

…PLC, Intact Mass analysis, and LAL assays.Results A total of 30 bsAbs were successfully produced in both double-tagged and non-tagged…

…arlatamab, epcoritamab, glofitamab, mosunetuzumab, talquetamab, teclistamab, and elranatamab. Eligibility criteria were abstracted for excl…

…32%). In FL, CAR-T products such as axicabtagene ciloleucel and lisocabtagene maraleucel achieve CR rates up to 94%, with median durations of remission …

… microbiota-preserving strategies could enhance the efficacy of BsAb therapy in MM.…

…gens expressed on distinct tumor and stromal cell compartments. BiCo-3 enhances efficacy of CD3-directed bsAbs across a broad range of…

…odynamic data to predict human PK and inform dose selection for bispecific antibodies. The approach serves as a viable alternative to animal testing,…

…vity and systemic safety of Y101S were assessed in vivo.Results MSA-2 combined with YM101 significantly inhibited tumor growth and im…

…nd T cells results in enhanced target cell killing when mAb and bsAb are given together. These data provide further support for eval…

…ivo, thereby validating these CD3 VHHs as an ideal platform for TCE engineering.…